Reported 2 days ago
H.C. Wainwright has reaffirmed its Buy rating for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) with a target price of $20 after Health Canada granted a Notice of Compliance for Amtagvi (lifileucel), a T cell immunotherapy for advanced melanoma. This marks the first T cell therapy approved for this indication in Canada, potentially boosting Iovance’s stock and opening doors for future international approvals. Despite its potential, other AI stocks are also being considered for investment due to their higher upside and lower risk.
Source: YAHOO